A Phase 1/2 trial evaluating the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ATA129 combination with KEYTRUDA® (pembrolizumab), in patients with platinum resistant or recurrent EBV-associated Nasopharyngeal Carcinoma (NPC)

Trial Profile

A Phase 1/2 trial evaluating the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ATA129 combination with KEYTRUDA® (pembrolizumab), in patients with platinum resistant or recurrent EBV-associated Nasopharyngeal Carcinoma (NPC)

Planning
Phase of Trial: Phase I/II

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Epstein-Barr virus-specific T-cell therapy Atara/MSKCC (Primary) ; Pembrolizumab (Primary)
  • Indications Nasopharyngeal cancer
  • Focus Adverse reactions
  • Sponsors Atara Biotherapeutics
  • Most Recent Events

    • 25 Apr 2017 New trial record
    • 21 Apr 2017 According to an Atara Biotherapeutics media release, company is planning to start this trial in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top